- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
First-half results don’t impress Siemens
German technology conglomerate Siemens AG enjoyed healthy revenue growth of 15% for the financial period from October 1997 to June 1998, but the Munich company said it was unhappy with its 5% increase in earnings for the period. Siemens plans to
German technology conglomerate Siemens AG enjoyed healthy revenue growth of 15% for the financial period from October 1997 to June 1998, but the Munich company said it was unhappy with its 5% increase in earnings for the period. Siemens plans to accelerate its restructuring program to bring profit growth to acceptable levels.
Siemens implemented a restructuring last year to improve the companys profit outlook, divesting noncore businesses and cutting costs in several divisions (SCAN 9/17/98). Earnings growth since then has not met the companys expectations, however, according to Siemens AG president and CEO Heinrich von Pierer. Siemens will pursue additional moves, such as divestitures and reorganizations, he said.
The companys Medical Engineering Group was cited as an example of a successful turnaround effort. The division was one of the groups reorganized last year, and costs associated with the effort contributed to a major loss for the unit in 1997. With the restructuring behind it, Medical Engineering turned in double-digit growth and should achieve a profit this year of hundreds of millions of marks, Pierer said.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
